Biggest News Aggregation in the World
📰 Cameron Durrant News

Page 4 - Cameron Durrant News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Cameron Durrant. Real-time updates on events, politics, business and more.

Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels

03.01.2022 - Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced that a manuscript ... Seite 1
United Kingdom Cameron Durrant Dale Chappell Humanigen Inc Chief Scientific Officer Chief Executive Officer

The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results

02.12.2021 - Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, announced today The Lancet ... Seite 1
Cameron Durrant Zelalem Temesgen Humanigen Inc Lancet Respiratory Medicine Mayo Clinic

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Humanigen, Inc.: The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results

Lenzilumab is a variant-agnostic therapeutic that targets the dysregulated host immune response, an approach which may be of greater value than targeting the virus in hospitalized patients1 Per
United Kingdom Ken Trbovich Cameron Durrant Zelalem Temesgen Exchange Commission Humanigen Inc

Humanigen, Inc.: Humanigen announces preparation of Phase 1b study of ifabotuzumab in solid tumors following presentation of Phase 1 study results at EANM'21

An abstract showing tumor specific targeting at all known tumor sites in glioblastoma patients, with no normal tissue uptake of ifabotuzumab, from a Phase 1 study will be presented at EANM'21
United Kingdom Ken Trbovich Cameron Durrant Andrew Scott Austin Health Trobe University

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science